Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential

i think this news is pretty major, my reckoning we will get more news than bargained for

HenryFord - 7 Dec'06 - 20:05 - 14498 of 14516

BioMerieux, awarded 54.5m, will focus on the development of new molecular diagnostic platforms to perform high-added-value analyses of infectious diseases and cancers.

http://www.drugresearcher.com/news/ng.asp?n=72476-merieux-alliance-transgene-aii-personalised-medicine-biomerieux

getting back to the RELEVANT RESEARCH

HenryFord - 7 Dec'06 - 20:07 - 14499 of 14516

http://www.investegate.co.uk/Article.aspx?id=200607120700230534G

Cannoncan - 7 Dec'06 - 20:33 - 14500 of 14516 edit

;-)

HenryFord - 7 Dec'06 - 20:44 - 14501 of 14516

You can clearly see the "Personalised Medicine" Potential in the diagnostic side of Eirx. It's on a par commercially with a blockbusting drug down the road.
You can also see that its the Colerectal Cancer Research of Eirx that BioMeriux are clearly after, a collaboration with a $2B sales pa company and reciprocal IP deal is clearly not to be sniffed at.

Check out the BBC web-site for RENE

http://news.bbc.co.uk/2/hi/health/6207236.stm

.

This is about to rise up now the MM's have duped the weak holders

From the other side:

ReNeuron is presenting at the following conferences:

Genesis VI 12 December 2006 London, England


The Leading biotechnology networking conference

The annual Genesis Conference is the London Biotechnology Networks premier event. Now in its sixth year, Genesis has established itself as a must in the biotech calendar.

Building on the success of 2005, the 2nd Annual UK Biotechnology Company Showcase will this year be an integral part of the event held the preceding day, Monday 11th December 2006.

We are delighted to announce that the Society for Medicines Research, founded in 1966 has agreed to hold their December meeting with us, alongside the UK Biotechnology Company Showcase. This will be the first time two such events, one aimed at the scientific and technical aspects of BioPharma R&D, the other at the corporate development and partnering aspects, are delivered in this way. The sessions will be themed and complementary, allowing each delegate the option to listen within their chosen therapeutic field or cross-discipline as the day progresses.

The London Edge Biotechnology Executive Reception being held on the eveing of 11th December is the next step in the London Edge series being spearheaded by the Londoin Stock Exchange.

In response to feedback from delegates, this year we have also created more depth to the program in the two areas requested: Biomedical Innovation and presentations for international companies. The "Biomedical Innovation Showcase" in the afternoon is being led by Dr Vivienne Cox of UK Bioscience Consultants and will showcase numerous near market medical technology opportunities. We have two opportunities to see leading international companies: "All I want for Xmas...." where six companies actively seeking in-licensing opportunities will present their wish list, and the "International Company Showcase" is being organised by WOCP and sponsored by International Business Wales

The emphasis at Genesis is on the cost effective networking opportunity it provides for the 700+ delegates, complementing the larger more costly partnering events. Such a route enables companies of all sizes to participate fully thereby developing the partnering and investment strategy form a position of knowledge.

Info is on there Web Site.

http://www.reneuron.com/

http://www.londonbiotechnology.co.uk/genesis/

News out today USA with regard to RENE, set for lift-off

get in ERX NOW,

Luckypicker - 12 Dec'06 - 12:07 - 14953 of 14962


"john"
12/12/2006 11:53
To
XXX

Subject
Re: Shareholder Question





Hi
As CEO as just returned from the US completing statements
J
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From: XXXX
Date: Tue, 12 Dec 2006 11:51:22
To:"John K Pool"
Subject: Re: Shareholder Question

Dear John

why no RNS??






Presenting it like this would've helped - nice find though.- I believe this is worthy of RNS

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
ABOUT LY2181308 AND SURVIVIN
LY2181308 targets survivin, a molecule that supports the survival of
cells that would normally die through programmed cell death or apoptosis.
Survivin helps in the abnormal growth of cancer cells, and is abundant in
many types of cancers, including colon, brain, lung, skin and others, but
nearly nonexistent in normal cells and tissues.

------------------------------------------------------------------------------------------------------------
-

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

------------------------------------------------------------------------------------------------------------
-
CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Eli Lilly and
Company (NYSE: LLY) highlighted two antisense oligonucleotide (ASO) drugs
in its "Update to Wall Street on Strategic Priorities and Pipeline
Progress" on Thursday. Advances with both survivin ASO (LY2181308) and
eIF-4E ASO (LY2275796) drugs were singled out among Select Early- to
Mid-Stage Pipeline Developments. Based on promising activity in early
studies, Lilly said that it is initiating Phase 2 trials for survivin ASO
in a broad range of cancers including liver cancer, prostate cancer, acute
myelogenous leukemia, ovarian cancer and non-small cell lung cancer; the
first of these trials is planned to begin this month. Lilly also said that
the Phase 1 development program for eIF-4E ASO is progressing well.
"We are pleased that Lilly includes our collaboration drugs among its
selected strategic priorities," commented C. Frank Bennett, Ph.D., Isis'
Senior Vice President of Research. "These drugs resulted from our
productive collaboration and Lilly's broad investment in antisense
technologies. We continue to work together and hope that additional drugs
will arise from our collective efforts. Lilly's progress with these
anti-cancer drugs emphasizes the broad therapeutic potential of Isis'
platform antisense technologies, and underscores our strategy of working
with partners to expand the scope of our development pipeline.





Kind regards

Their US partner 'Stem Cells Inc' has released positive treatment update.
With market over there opening 2.00pm GMT expect further gains later.

Up 12% today. Could be a lot higher shortly

Drop 19% - why is that?

profit taking

Stem cell technology (hybrid) in negative light this morning on BBC, see http://news.bbc.co.uk/1/hi/health/6230945.stm.
Should not affect ReNeuron though

It is likely that the BBC 'news' is in mode of "there's no such thing as bad news". Those in the know re SCR appreciate the significant benefits and therefore RENE has a great future. That type of news only serves to make more investors aware and hence quid pro quo.

More negative news for RENE...clinical study put on hold by FDA

ReNeuron Group plc
09 January 2007

Regulatory Update

Guildford, UK, 9 January 2007: ReNeuron Group plc (LSE: RENE) today provides an update regarding its recently filed Investigational New Drug (IND) application
to commence a Phase I clinical study for its ReN001 stem cell therapy for
stroke. The US Food and Drug Administration (FDA) has orally confirmed that it
has placed the proposed clinical study on hold. A telephone conference call
with the FDA to discuss the application is expected to take place later this
week, following which the Company will make a further announcement.



Michael Hunt, Chief Executive Officer of ReNeuron, said:



'We are encouraged to be able to engage in an immediate dialogue with the FDA
regarding our IND application, now that the initial review process has taken
place. Given the ground-breaking nature of our ReN001 therapy and the lack of
comparable approaches addressing stroke, it is not surprising that the FDA might
wish to raise questions or make comments at this point in the approval process.
We look forward to a constructive dialogue with the FDA and, in the meantime, we
continue with our ongoing preparations for the initial ReN001 clinical study.'

Buying opp? RENE Bid: 36p Offer: 38.5p Change: -7.25

I think this will go down to 25p.

HYLEO
Not exactly 25p. At current 46p think they have a bit further to go

It looks more like it is heading for single figures.